Inflation's impact on patient treatment easing, survey shows

20 June 2023

Healthcare cost pressures have started easing in all but one of the seven major markets in 2023, as physicians noticed a decline in the number of patients postponing or stopping treatments compared to 2022.

A survey by GlobalData, titled The Impact of Inflation on the Healthcare Sector - Physician Perspective – H1 2023, found that the UK was the only market where this was not the case, as the country that had the highest inflation rate in April 2023 as compared to other researched markets.

These findings across the seven major markets of the USA, France, Germany, Italy, Spain, UK and Japan, are reflected in the table below. A total of 568 healthcare professionals participated in the 2023 survey, whereas in 2022 the number was 358.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK